Efficacy of abobotulinumtoxinA versus onabotulinumtoxinA for the treatment of refractory neurogenic detrusor overactivity: a systematic review and indirect treatment comparison.

Francisco Cruz,Natalya Danchenko,Kyle Fahrbach,Andreas Freitag,Jialu Tarpey,John Whalen

Journal of medical economics（2023）

引用 1|浏览8

暂无评分

摘要

There may be potential advantages of aboBoNT-A over onaBoNT-A, in terms of UI reduction, in patients with refractory NDO. More confirmatory studies are needed owing to sparsity of current evidence.

查看译文

关键词

I,I1,I10,I19,Neurogenic detrusor overactivity,abobotulinumtoxinA,botulinum toxin type A,indirect treatment comparison,onabotulinumtoxinA,urinary incontinence

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要